Albumin - low
Also known as: Hypoalbuminemia
Methodology & AI Transparency ⓘ
Albumin - low Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Albumin - low (also termed Hypoalbuminemia) (E88.09; Weight Management & Metabolic Syndrome) utilize body composition DEXA in Albumin - low (E88.09: or waist-circumference anthropometry) and objective Waist-to-Height Ratio [Albumin - low E88.09] targets (< 0.50 (E88.09)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Synonyms for Albumin - low (E88.09): Hypoalbuminemia (Weight & Metabolism).
- 3 Typical cash cost range: Clinicians assessing Albumin - low focus on hypothalamic arcuate nucleus in Albumin - low (E88.09: leptin resistance) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Albumin - low monitoring tracks Waist-to-Height Ratio [Albumin - low E88.09] toward < 0.50 (E88.09).
Ask our AI Specialists anything about Albumin - low
What Is Albumin - low?
Physicians managing Albumin - low (also termed Hypoalbuminemia) (E88.09; Weight Management & Metabolic Syndrome) utilize body composition DEXA in Albumin - low (E88.09: or waist-circumference anthropometry) and objective Waist-to-Height Ratio [Albumin - low E88.09] targets (< 0.50 (E88.09)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
In Albumin - low (E88.09), physiological disruption stems from hypothalamic arcuate nucleus in Albumin - low (E88.09: leptin resistance), informing Weight Management & Metabolic Syndrome protocols that track HOMA-IR Insulin Resistance in Albumin - low (E88.09: Index) (< 1.4 (E88.09)).
Common Symptoms & Clinical Signs
- • Presentation of Albumin - low (E88.09): daytime sluggishness or in Albumin - low (E88.09: loud snoring linked)
- • Secondary Albumin - low clinical sign: central abdominal visceral in Albumin - low (E88.09: fat accumulation resistant)
- • Symptom flares in Albumin - low correlating with Waist-to-Height Ratio [Albumin - low E88.09] deviation outside < 0.50 (E88.09)
- • Functional weight & metabolism impact requiring body composition DEXA in Albumin - low (E88.09: or waist-circumference anthropometry) evaluation (E88.09)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Albumin - low Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.09 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Albumin - low E88.09] | < 0.50 (E88.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Albumin - low (E88.09: Index) | < 1.4 (E88.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Albumin - low (E88.09: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E88.09) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Albumin - low
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Albumin Human Albuminex • RxCUI RXN-642082510-2793 | Human Serum Albumin | 76% | $2.7800 | $ 121.09 /mo |
| Volumex (Iodinated I-131 Albumin) Volumex • RxCUI RXN-B509147720 | Radiopharmaceutical Activity [MoA] | 77% | $0.5200 | $ 45.94 /mo |
| Megatope (Iodinated I-131 Albumin) Megatope • RxCUI RXN-B509147731 | Radiopharmaceutical Activity [MoA] | 77% | $3.0700 | $ 229.54 /mo |
| Iodinated I-131 Albumin Megatope, Volumex • RxCUI RXN-509147731-1994 | Radiopharmaceutical Activity [MoA] | 75% | $0.5600 | $ 31.18 /mo |
| Albuminex (Albumin Human) Albuminex • RxCUI RXN-B642082510 | Human Serum Albumin | 77% | $1.1500 | $ 91.30 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Albumin - low)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on GLP-1-based therapies and limb outcomes in: What a 240,000-Participant Study Found In real-world PAD populations, GLP-1-based therapies are associated with meaningful reductions in both limb and heart and blood vessel outcomes. Diabetes research and clinical practice • 2026-06-15 • Meta-Analysis | N = 240,000 | 94/100 | PMID 42009258 ↗ |
| New Insights on Weight maintenance and additional weight loss with liraglutide after: What a 422-Participant Study Found Liraglutide, with diet and exercise, maintained weight loss achieved by caloric restriction and induced further weight loss over 56 weeks. International journal of obesity (2005) • 2013-11-15 • Randomized Controlled Trial | N = 422 | 93/100 | PMID 23812094 ↗ |
| New Insights on Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a: What a 360-Participant Study Found This might suggest a varying degree of importance of DPP-4 as a pathophysiological factor in T2D-associated kidney disease. Diabetes, obesity & metabolism • 2021-08-15 • Phase III Randomized Trial | N = 360 | 93/100 | PMID 33881796 ↗ |
| New Insights on Effect of Subcutaneous Semaglutide vs Placebo as an add-on booster to Intensive: What a 611-Participant Study Found Of 611 randomized participants (495 women [81.0%], mean age 46 years [SD, 13], body weight 105.8 kg [SD, 22.9], and body mass index 38.0 [SD, 6.7]), 567 (92.8%) completed the trial, and 505 (82.7%) were receiving treatment at... JAMA • 2021-04-13 • Phase III Randomized Trial | N = 611 | 93/100 | PMID 33625476 ↗ |
| What the Latest Evidence Really Says About GLP-1 Receptor/Dual Agonists for Weight Tirzepatide and Semaglutide_SC are most effective for clinically meaningful weight loss. Diabetes, obesity & metabolism • 2026-06-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 41872986 ↗ |
Albumin - low Patient Community & “People Like Me” Threads
Filter Albumin - low community threads and patient logs by age, biological sex, dosage, and treatment duration.